Interim report January - June 2013
Strong growth of US clinical sales (+48%) and volume of tests (+54%). Increased volume demonstrating customers see value in the utility of FeNO testing.
January – June 2013
- Global Net sales decreased by 9% to SEK 69.4m (76.0)*. Adjusted for currency fluctuations, net sales decreased by 5% Year over Year (Y-o-Y).
- Net sales for clinical use of NIOX MINO increased by 17% and in the US by 48% in local currency.
- Strategic sales/shipments (sales to Pharmaceutical companies and CRO’s for clinical trials) decreased by 55% to SEK 11.8m (26.3). These sales substantially fluctuate between quarters.
- Total worldwide number of tests sold (repeat and initial) reached over 1.0 (0.9) million tests, an increase of 13% Y-o-Y and in the US for clinical use by 54%.
- Total repeat test volume for clinical use increased by 18% and in the US with 28%.
- Gross Margin was 72% (71%).
- The loss after tax amounted to SEK 110.0m (80.5), corresponding to a loss per share before and after dilution of SEK 0.7 (0.7).
April – June 2013
- Global Net sales decreased by 4% to SEK 35.7m (36.9)*. Adjusted for currency fluctuations, net sales increased by 1% Y-o-Y (Year over Year).
- Net sales for clinical use of NIOX MINO increased by 22% and in the US by 47% in local currency.
- Strategic sales/shipments decreased by 50% to SEK 6.2m (12.5).
- Total worldwide number of tests sold (repeat and initial) reached over 0.5 (0.4) million tests, an increase of 24% Y-o-Y and in the US for clinical use by 62%.
- Total repeat test volume for clinical use increased by 25% and(in the US by 46%.
- Gross Margin was 70% (72%).
- The loss after tax amounted to SEK 55.7m (41.4), corresponding to a loss per share before and after dilution of SEK 0.4 (0.3).
- Through debt and a directed new share issue Aerocrine raised approximately SEK 324m (USD 50m) before expenses. Based on its long term plan, the company believes that this funding will be sufficient to reach positive cash flow and profitability.
- Georgia became the 37th state Medicaid program to reimburse FeNO testing in the U.S.
- Health Canada authorized Aerocrine’s latest version of NIOX MINO®.
- NIOX MINO® (version from 2008) has received market clearance in Japan by PMDA.
- ATS (American Thoracic Society) presented data of FeNO-testing in Overlap Syndrome.
- At the AGM, held on May 7, the board was re-elected with Rolf Classon as new chairman. It was further resolved to implement a board-share program (SAP-2013).
AEROCRINE IN BRIEF
| April - June | Jan - June | Rolling-12 | Full year | |||
| SEKm | 2013 | 2012 | 2013 | 2012 | –July - June | 2012 |
| Net sales | 35.7 | 36.9 | 69.4 | 76.0 | 140.4 | 147.0 |
| -of which strategic sales | 6.2 | 12.5 | 11.8 | 26.3 | 21.2 | 35.7 |
| Gross profit/loss | 25.0 | 26.5 | 50.2 | 53.8 | 102.6 | 106.2. |
| Gross margin % | 70% | 72% | 72% | 71% | 73% | 72% |
| Operating profit/loss | -52.6 | -41.7 | -106.1 | -77.4 | -225.8 | -197.1 |
| Net profit after tax | -55.7 | -41.4 | -110.0 | -80.5 | -231.1 | -201.6 |
| Cash flow, current operations | -54.1 | -34.3 | -118.2 | -81.3 | -221.1 | -184.2 |
| Total cash flow | 260.8 | 201.1 | 194.9 | 154.1 | 89.6 | 48.8 |
For further information, please contact:
Scott Myers, CEO: +46 768 788 379 or +1 970 368 0336
Michael Colérus, CFO: +46 8 629 07 85
www.aerocrine.com or www.niox.com
*Note all numbers in ( ) are the corresponding period previous year and in the same unit.
This is information that Aerocrine AB (publ) is required to publish in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. This information was submitted for publication on July 25, 2013, at 8.00 a.m.